Out“FOX”ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy - Top-Institutions - MDSpire

Out“FOX”ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy

  • By

  • Kristian M. Hargadon

  • June 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber/Harvard Cancer Center
    Dana-Farber/Harvard Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #4

    Stanford University
    Stanford University

    Stanford, California

    Key Differentiators

    • Oncology

  • #5

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

Original Source(s)

Out“FOX”ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy

  • by Kristian M. Hargadon

  • June 30, 2026

Related Content

Evaluating the accuracy and communication quality of large language models in Ewing sarcoma: a comparative analysis of ChatGPT, Claude, Gemini, DeepSeek, and Grok

Network analysis of distress, symptom burden, social support, and digital health literacy in older postoperative patients with gastric cancer

Distinct trajectories of low anterior resection syndrome following ileostomy reversal